Peptide LibraryLibidon
Libidon is a khavinson peptide bioregulator. The Khavinson bioregulator hypothesis holds that short peptides extracted from a given tissue act preferentially on that same tissue, with proposed effects on gene expression and protein synthesis. Most supporting work comes from a single research group, is published largely in Russian-language journals, and has not been independently replicated in controlled human trials.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
Vendor price snapshot
None of these listings has a price per mg to compare. From public vendor listings; confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 1
- Listed offers
- 2
- Price per mg
- —
Research summary
Peptide preparation derived from prostate tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Libidon itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Libidon profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Libidon dosage: no established human dose
Libidon has no established human dosage. It is sold as capsules described as a prostate peptide bioregulator, a tissue-derived peptide complex. No trial of it is registered on ClinicalTrials.gov, and no study of Libidon itself is indexed in PubMed. The nearest human evidence is for Prostatilen, a different prostate peptide medicine given as 3 mg rectal suppositories, which does not transfer to an oral capsule.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Libidon is marketed as a peptide complex from prostate tissue, sold as an oral capsule. No human, animal or cell study of this product is indexed in PubMed. The related trial used Prostatilen, a previously registered suppository medicine described as containing prostate-gland peptides, by a different route. Nothing here establishes a human dose, route or interval for Libidon.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Related prostate peptide medicine (analog) — Prostatilen in chronic prostatitis (2022)Clinical trial · Phase III randomised open-label trial of a different product (analog evidence)Studied an analog, not Libidon itself | Men aged 25–45 with chronic abacterial prostatitis and reproductive problems (n=98; 49 given Prostatilen as the comparison arm) | Prostatilen 3 mg rectal suppository | Rectal | Once daily | 10 days | Total motile sperm rose by 4.1% with Prostatilen; the zinc-containing version (Prostatilen AC) did better on sperm measures | Influence of adding zinc arginyle-glycinate to improve efficacy of bioregulatory peptides of the prostate gland in treatment of patients with impaired sperm parameters. Georgian Med News. 2022. |
Where sources disagree
- Daily capsule protocols for Libidon are published by sellers. No registered trial or indexed study reports a dose for it.
- Prostatilen, Libidon and prostamax are different products. The Prostatilen dose is for a rectal suppository and is not a dose for an oral capsule.
- Libidon is not a treatment for prostate disease or for sexual problems.
Science
Mechanism of Action
The Khavinson bioregulator hypothesis holds that short peptides extracted from a given tissue act preferentially on that same tissue, with proposed effects on gene expression and protein synthesis. Most supporting work comes from a single research group, is published largely in Russian-language journals, and has not been independently replicated in controlled human trials. Claims specific to the prostate preparation should be read as marketing rather than established pharmacology.
Studies
- Peptides and Ageing (class-level)
- Tissue-specific effects of peptides (class-level)
- Peptide bioregulation of aging: results and prospects (class-level evidence)
- Mechanisms underlying geroprotective effects of peptides (class-level evidence)
- Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b (class-level evidence)
Regulatory & research status
Libidon is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Research status | Research-only compound; no approval pathway listed |
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
—
Libidon side effects
No side effects listed yet for this entry.
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Libidon: frequently asked questions
What is Libidon?
Peptide preparation derived from prostate tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Libidon itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators.
How does Libidon work?
The Khavinson bioregulator hypothesis holds that short peptides extracted from a given tissue act preferentially on that same tissue, with proposed effects on gene expression and protein synthesis. Most supporting work comes from a single research group, is published largely in Russian-language journals, and has not been independently replicated in controlled human trials.
Is Libidon FDA approved?
No. Libidon is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Libidon?
Compounds most often compared with Libidon include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Class-level evidence — Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett, 2002External reference
- Class-level evidence — Tissue-specific effects of peptides. Bull Exp Biol Med, 2001External reference
- Class-level evidence — Peptide bioregulation of aging: results and prospects — Biogerontology, 2010External reference
- Class-level evidence — Mechanisms underlying geroprotective effects of peptides — Bull Exp Biol Med, 2002External reference
- Class-level evidence — Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b — Mol Biol (Mosk), 2019External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3
This Libidon profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Libidon research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →